Li TJ. Integrating hepatitis C care into human immunodeficiency virus clinics in the direct-acting antiviral era: From biological disadvantage to structural opportunity. World J Gastroenterol 2026; 32(36): 118426 [DOI: 10.3748/wjg.118426]
Corresponding Author of This Article
Tian-Ju Li, PhD, Department of Infectious Diseases, Beibei Affiliated Hospital of Chongqing Medical University, No. 69 Jialing Village, Beibei District, Chongqing 400700, China. tianjulee@126.com
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Li TJ. Integrating hepatitis C care into human immunodeficiency virus clinics in the direct-acting antiviral era: From biological disadvantage to structural opportunity. World J Gastroenterol 2026; 32(36): 118426 [DOI: 10.3748/wjg.118426]
World J Gastroenterol. Sep 28, 2026; 32(36): 118426 Published online Sep 28, 2026. doi: 10.3748/wjg.118426
Integrating hepatitis C care into human immunodeficiency virus clinics in the direct-acting antiviral era: From biological disadvantage to structural opportunity
Tian-Ju Li
Tian-Ju Li, Department of Infectious Diseases, Beibei Affiliated Hospital of Chongqing Medical University, Chongqing 400700, China
Author contributions: Li TJ contributed to the concept, design, manuscript writing, and editing, as well as the review of the literature.
AI contribution statement: No AI was used to generate the manuscript, analyze data, create images, or generate references. Only ChatGPT was used for language polishing in the final revision due to submission time constraints.
Supported by the Chongqing Public Health Key Specialty Project, and the Natural Science Foundation of Chongqing Municipality, No. Cstc2021jcyj-msxmX1219.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Tian-Ju Li, PhD, Department of Infectious Diseases, Beibei Affiliated Hospital of Chongqing Medical University, No. 69 Jialing Village, Beibei District, Chongqing 400700, China. tianjulee@126.com
Received: January 2, 2026 Revised: February 2, 2026 Accepted: March 3, 2026 Published online: September 28, 2026 Processing time: 232 Days and 9.9 Hours
Core Tip
Core Tip: In the interferon-based treatment era, human immunodeficiency virus (HIV) coinfection was associated with poorer hepatitis C virus (HCV) outcomes. In contrast, recent evidence from Park et al in the direct-acting antiviral era suggests that achieving sustained virologic response may substantially narrow survival differences between individuals living with HIV/HCV and those with HCV monoinfection. Residual adverse outcomes increasingly reflect attrition across the care cascade and post-cure metabolic and non-liver risks rather than ongoing viral effects alone. Accordingly, integrated care models within HIV clinics, coupled with structured post- sustained virologic response surveillance, are essential to translate virologic cure into durable long-term benefit.
